PE Staff

Boehringer Ingelheim has licensed a preclinical antibody program from Immunitas Therapeutics for inflammatory diseases, signaling continued demand for earlier-stage immunology assets.

The agency converted Braftovi’s accelerated approval to full approval after Phase III BREAKWATER data demonstrated significant improvements in progression-free and overall survival in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer.

The approval of Keytruda (pembrolizumab) and Keytruda Qlex was supported by Phase III KEYNOTE-B96 data showing statistically significant improvements in progression-free and overall survival in patients with PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma.

Five key takeaways from the Future Investment Initiative panel on the Gulf region’s growing role in global VC.

The Aligos Therapeutics chairman, president, and CEO discusses his journey to building his own company and bringing an experienced team along with him.

Zura Bio’s CEO and director Robert Lisicki discusses how his path to leadership taught him the importance of building a team that can deliver even when the goals don’t seem to be achievable.

Co-founder and CEO of CUTISS, Daniela Marino, PhD, talks about her switch from academia to the biotech industry and her 16-year journey developing a first-in-class personalized tissue therapy.

Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial intelligence in the drug discovery process.

Casey McPherson, Founder and CEO of AlphaRose Therapeutics (formerly Chrysalis Genetics), talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare diseases.

Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York's thriving bioscience ecosystem, and outlines her vision for the state as a global biotech hub.

Joseph Panetta, President and CEO of Biocom California, shares his insights on biotech industry trends, policy challenges, and educational initiatives, drawing from over 25 years of leadership in California’s thriving life sciences sector.

Max Colao, CEO of OncoVerity, discusses his extensive experience in the biotech industry and shares how his company is harnessing computational biology and machine learning to develop personalized cancer treatments that aim to reshape the future of oncology care.

Elyse Blazevich discusses the Colorado Bioscience Association’s efforts to support the state’s life sciences sector by fostering partnerships, advocating for industry growth, and building a diverse talent pipeline.

In this interview, Melissa Krebs,Ph.D., CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

Meet the rest of 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history?